Use of NK-1 receptors antagonists for treating schizophrenic disorders
US6100256A · kind A · utility
2Cited by
10References
11Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Jun 11, 1998 |
| Grant date | Aug 8, 2000 |
| Priority date | — |
| Expiry date | Jun 11, 2018 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K31/675
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention provides a method for the treatment or prevention of schizophrenic disorders using an orally active, long acting, CNS-penetrant NK-1 receptor antagonist and pharmaceutical compositions comprising such a NK-1 receptor antagonist.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.